46837-95-0

Basic information

• Product Name: 4-[2-(3-nitrophenyl)ethenyl]pyridine
• Synonyms: 4-[2-(3-nitrophenyl)ethenyl]pyridine
• CAS NO: 46837-95-0
• Molecular Formula: C₁₃H₁₀N₂O₂
• Molecular Weight: 226.2307
• Mol File: 46837-95-0.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 385.7°Cat760mmHg
• Flash Point: 187.1°C
• Appearance: /
• Density: 1.273g/cm³
• Vapor Pressure: 8.28E-06mmHg at 25°C
• Refractive Index: 1.694
• CAS DataBase Reference: 4-[2-(3-nitrophenyl)ethenyl]pyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-[2-(3-nitrophenyl)ethenyl]pyridine(46837-95-0)
• EPA Substance Registry System: 4-[2-(3-nitrophenyl)ethenyl]pyridine(46837-95-0)

Safety Data

• Hazardous Substances Data: 46837-95-0(Hazardous Substances Data)

Usage

Physical properties

yellow to brownish solid

Solubility

sparingly soluble in water, more soluble in organic solvents

Uses

intermediate in synthesis of other chemicals, reagent in organic chemistry reactions
Biological and pharmacological activities
Potential use in pharmaceutical development

Hazardous properties

should be handled with care
Should only be used by trained professionals in a controlled laboratory setting

InChI:InChI=1/C13H10N2O2/c16-15(17)13-3-1-2-12(10-13)5-4-11-6-8-14-9-7-11/h1-10H

Upstream product

• 108-89-4 picoline 
• 108-24-7 acetic anhydride 
• 99-61-6 3-nitro-benzaldehyde 
• 100-43-6 4-vinylpyridine 
• 645-00-1 m-iodonitrobenzene 
• 585-79-5 m-nitrobromobenzene 
• 13331-27-6 m-nitrobenzene boronic acid 

Downstream Products

• 1401773-86-1 (E)-N-(3-diethylaminopropyl)-3-[3-(2-pyridin-4-ylvinyl)phenylamino]benzenesulfonamide 
• 1173003-01-4 N-(3-methyl-butyl)-3-[3-((E)-2-pyridin-4-yl-vinyl)-phenylamino]-benzamide 
• 1173003-00-3 N-(3-diethylamino-propyl)-3-[3-((E)-2-pyridin-4-yl-vinyl)-phenylamino]-benzamide 
• 388627-91-6 3-(4-pyridinyl)ethylaniline 
• 32598-04-2 (E)-3-(2-(pyridin-4-yl)vinyl)aniline 

Relevant articles and documents

Compounds for use as therapeutic agents affecting p53 expression and/or activity

The present invention relates to compound (I) wherein R1 and R2 independently represent a hydrogen atom, a (C1-C4)alkoxy group, a fluoro(C1-C4)alkoxy group, a hydroxyl group, a benzyloxy group, a di(C1-C4)alkylamino group, a pyridyl-vinyl group, a pyrimidinyl-vinyl group, a styryl group, or a -NHCOphenyl group; R3, R4 and R5 independently represent a hydrogen atom, a (C1-C4)alkyl group, a CONHR6 group, a -CONR7R8 group, a -SO2NHR6 group, or a heteroaryl group optionally substituted by a halogen atom, a -(CH2)nNR7R8 group or a hydroxy(C1-C4)alkyl group; R6 represents a hydrogen atom, a -(CHR9)m(CH2)nNR7R8 group or a (C1-C6)alkyl group optionally substituted by a hydroxyl group; or anyone of its pharmaceutically acceptable salt, for use as an agent for preventing, inhibiting or treating a disease in a patient suffering thereof, said disease involving a deregulated p53. Some of said compounds are new and also form part of the invention.

Oxindole-based inhibitors of cyclin-dependent kinase 2 (CDK2): Design, synthesis, enzymatic activities, and X-ray crystallographic analysis

Two closely related classes of oxindole-based compounds, 1H-indole-2,3-dione 3-phenylhydrazones and 3-(anilinomethylene)-1,3-dihydro-2H-indol-2-ones, were shown to potently inhibit cyclin-dependent kinase 2 (CDK2). The initial lead compound was prepared as a homologue of the 3-benzylidene-1,3-dihydro-2H-indol-2-one class of kinase inhibitor. Crystallographic analysis of the lead compound bound to CDK2 provided the basis for analogue design. A semiautomated method of ligand docking was used to select compounds for synthesis, and a number of compounds with low nanomolar inhibitory activity versus CDK2 were identified. Enzyme binding determinants for several analogues were evaluated by X-ray crystallography. Compounds in this series inhibited CDK2 with a potency ～10-fold greater than that for CDK1. Members of this class of inhibitor cause an arrest of the cell cycle and have shown potential utility in the prevention of chemotherapy-induced alopecia.